Fenben Lab
Fenben Lab is one of the most visible brands in the consumer fenbendazole market. Registered in Lithuania and operating under the corporate entity Canchema UAB ↗, it presents itself as a well-established, quality-focused supplier with over 12 years of experience, an international warehouse network, and a 4.8/5 Trustpilot rating based on 2,661 reviews ↗.
At first glance, the operation appears credible. A closer examination, however, reveals a concealed multi-brand ownership network used to reinforce its perceived market dominance, self-issued quality certifications, multiple independent purity tests showing results far below advertised claims, an active federal lawsuit involving its parent entity, and growing indications of coordinated manipulation of public perception. This review documents these findings.
Full Brand & Product Review
Overall Rating: 3.2 / 10
Overview
2026.04.07
REGISTRATION
Lithuania (Vilnius), 2014
PRODUCT OPTIONS
222 mg, 444 mg (capsules )
INDEPENDENT CERTIFICATE OF ANALYSIS
In-house testing, no independent laboratory oversight
PRODUCER
No specific laboratory indicated
SUBSIDIARY BRANDS
Fenzol, Naresun Fenben Pro
These brands present themselves as independent competitors. In reality, they are not. Adisant UAB holds USPTO trademarks for both Fenzol and Naresun. A Certificate of Analysis issued for Fenzol was found to contain the email address info@naresun.com — a clerical oversight that confirms a shared production origin. Both certificates carried identical issue dates and identical purity results.
This matters for one key reason: a buyer comparing Fenben Lab with its apparent competitors may unknowingly be comparing the same operation against itself. The competitive landscape surrounding this product is, at least in part, artificially constructed.
Investigation:
The Pelakauskas Network
Fenben Lab is operated by Canchema UAB ↗, a Lithuanian chemical company registered at Piliakalnio g. 7, Vilnius, with Vytautas Pelakauskas listed as director in the Lithuanian business registry. This corporate identity is not disclosed on the Fenben Lab website or in any customer-facing materials. Buyers purchasing from fenbenlab.com have no clear way of identifying the manufacturer, its official registration, or the party legally responsible for the product.
The ownership structure becomes more significant in the broader context. Canchema UAB is not the only Pelakauskas-family entity operating in this market. Curaltus UAB ↗, directed by Linas Pelakauskas and registered at the same Vilnius address, along with Adisant UAB ↗, incorporated in 2020 in Švenčionys, collectively control at least three additional consumer fenbendazole brands: Fenzol, Naresun, and FenbenPro.
The fenbendazole.org Conflict of Interest
A further concern involves fenbendazole.org, which presents itself as an independent ranking platform. At first glance, Fenben Lab appearing in the top five is not unusual. It is an established brand with strong visibility and review volume. The issue is Fenzol.
Fenzol also ranks in the top five↗ despite significantly lower visibility, fewer reviews, and no clear market standing that would justify such placement. Meanwhile, more established brands are absent.
The question is simple: why?
The answer lies in ownership.
Fenzol is trademarked by Adisant UAB, part of the same Pelakauskas family network that operates Fenben Lab through Canchema UAB. Both brands in this “independent” ranking trace back to the same operation.
No methodology is disclosed.
No affiliations are declared.
What appears to be an objective ranking may, in reality, be self-promotion.
This is not independent analysis. It is marketing presented as neutrality.
Criteria Ratings
1. Information Transparency
Rating: 1 / 10
Key facts: ownership, manufacturing entity, corporate identity — are omitted entirely from the customer experience.
Quality verification is internal.
Certificates of Analysis are issued by the manufacturer itself, with no independent laboratory oversight.
When independent testing contradicted the brand’s claims, the response was not to verify or refute the findings through credible third-party analysis.
The response was to eliminate third-party testing altogether. That decision is not neutral. It removes accountability.
Fenben Lab claims over 20 years of expertise, a figure repeated prominently across its website and product listings.
Canchema UAB, the legal entity behind the brand, was incorporated in 2014.
That makes the company approximately 12 years old at the time of this review, not 20+. The origin of the additional eight years is not explained anywhere on the site. Whether this refers to informal activity predating incorporation, experience claimed across related entities, or simply an inflated marketing figure, it cannot be verified and it is not disclosed. A brand that opens with a fabricated or unverifiable founding claim does not earn the benefit of the doubt on other claims it makes about itself.
2. Label Accuracy
Rating: 1 / 10
Fenben Lab consistently claims ≥99% purity, supported only by internally issued certificates.
Independent testing tells a different story:
-
Dr. William Makis (2024): 56% purity (UPLC-PDA testing)
-
Spectrix Analytical Services: 7.05% purity
-
Third reviewer: <5% purity
Three independent tests. Three results between 5% and 56%. No independent result supports the 99%+ claim.
For a product used in dosing-sensitive protocols, this discrepancy is not trivial.
3. Product Definition
Rating: 5 / 10
The compound is correctly identified as fenbendazole, a well-characterized benzimidazole anthelmintic with an established chemical profile. Fenben Lab offers multiple dosage formats, including 222 mg, 444 mg, and 500 mg capsules, as well as powder formulations. Product specifications are clearly presented and consistently described.
However, correct identification does not guarantee product reliability. If the labeled concentration does not reflect the actual composition, the product is not truly defined where it matters most.
4. Manufacturer Traceability
Rating: 2 / 10
Canchema UAB is technically discoverable through public registries, but this information is not presented anywhere in the customer experience.
The relationship between Fenben Lab and its sister brands was not disclosed, it was uncovered through documentation inconsistencies and registry cross-referencing.
Packaging comparisons between Fenben Lab and FenbenPro show nearly identical design, materials, and presentation, suggesting shared manufacturing.
Undisclosed multi-brand segmentation presented as independent competition constitutes consumer deception rather than standard market strategy.
5. Availability & Distribution
Rating: 8 / 10
This is the brand’s strongest area.
Fenben Lab operates warehouses across the US, UK, and EU, enabling fast delivery, broad international coverage, and efficient logistics.
Customer feedback consistently highlights reliable shipping, packaging quality, and order accuracy.
6. Public Feedback Patterns
Rating: 2 / 10
The 4.8/5 Trustpilot rating ↗ requires context.
Fenben Lab operates within a network of related brands, each accumulating separate reviews. This fragments and amplifies perceived credibility.
Customer reports also indicate:
Delayed support responses
Difficulty obtaining refunds
Suppression of negative feedback
Trustpilot engagement appears selective — responsive to positive reviews but largely absent on critical ones.
There are also recurring reports of coordinated social media promotion across health-related groups. While not independently verified, the pattern is consistent.
Additionally, Fenben Lab has publicly attacked competitors while simultaneously operating undisclosed competing brands — raising further concerns about credibility.
7. Legal Proceedings
On March 9, 2026, a federal lawsuit was filed in the U.S. District Court for the District of New Jersey: Happy Healing Inc. et al v. UAB Canchema et al, docket 3:2026cv02430 ↗. UAB Canchema is the Lithuanian parent entity behind Fenben Lab. The case is active. Full claim details are not yet publicly available. For buyers in the United States, this is a material development: the manufacturer behind Fenben Lab is now a named defendant in active U.S. federal litigation.
Summary Scorecard
Main Conclusion
Fenben Lab is not an amateur operation. It demonstrates strong logistics, consistent branding, and market presence.
However, the totality of evidence — undisclosed ownership, lack of independent verification, significant discrepancies in purity testing, a concealed multi-brand network, potential conflicts of interest in external rankings, reports of feedback manipulation, and ongoing legal proceedings, places it among the least transparent and least verifiable brands in this category.
The people most likely to be buying fenbendazole are managing serious illness and following dosing-sensitive protocols. They deserve to know what they are actually buying.